<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-102 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-102</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-102</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <p><strong>Paper ID:</strong> paper-fd8c293ec07c9a03f0de0c9eb752266f199977b1</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/fd8c293ec07c9a03f0de0c9eb752266f199977b1" target="_blank">A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.</a></p>
                <p><strong>Paper Venue:</strong> Genome Research</p>
                <p><strong>Paper TL;DR:</strong> It is demonstrated that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggested the chimeric oncogene as a promising molecular target for the personalized diagnosis and treatment of lung cancer.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e102.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e102.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KIF5B-RET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KIF5B-RET gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A recurrent oncogenic gene fusion in lung adenocarcinoma that joins the N-terminal portion of KIF5B (containing a coiled-coil dimerization domain) to the C-terminal tyrosine kinase domain of RET, producing a constitutively active chimeric RET kinase.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Index case (AK55): a 33-year-old, never-smoker male with poorly differentiated, metastatic lung adenocarcinoma negative for EGFR, KRAS, and EML4-ALK by clinical testing; discovery used paired tumor (liver metastasis) and normal (blood) tissue. Replication cohort: 5 additional triple-negative (EGFR/KRAS/EML4-ALK-negative) primary lung adenocarcinomas (LC_S1-LC_S5) and 15 additional double-negative (EGFR and EML4-ALK negative; KRAS status unknown prior to study) primary lung adenocarcinomas (LC_S6-LC_S20).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>21</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Tumors negative for the canonical 'triple-markers' used here: EGFR (exons 18-21), KRAS (exon 2), and EML4-ALK fusion (triple-negative). A subset of replication samples were 'double-negative' (EGFR- and EML4-ALK-negative; KRAS status unknown).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Replication: 2/20 (10%) primary lung adenocarcinomas in the replication cohort harbored KIF5B-RET (LC_S2 among 5 triple-negative = 1/5; LC_S6 among 15 double-negative = 1/15). Including index case: 3/21 (~14.3%) across all primary samples assayed in this study. The authors estimate a population frequency ~6% (see paper calculations).</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Whole-genome sequencing (Illumina Genome Analyzer IIx / HiSeq2000; liver metastasis WGS depth ~47.77×, blood ~28.27×) and transcriptome (RNA-seq) sequencing (Illumina; ~89.7 M transcriptome reads). Fusion detection used discordant paired-end and spanning reads (GFP fusion program, GSNAP alignment). Validation by inversion-specific genomic PCR and cDNA PCR with Sanger sequencing. Structural/3D modelling by PHYRE2.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>KIF5B-RET fusion (10.6-Mb pericentric inversion on chromosome 10 producing chimeric KIF5B-RET transcript)</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>gene fusion (structural variant / chromosomal inversion)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>RET proto-oncogene (receptor tyrosine kinase; RTK pathway), KIF5B (kinesin family member providing N-terminal coiled-coil dimerization). Implicates RTK/MAPK (canonical RET downstream signaling) — an RTK-driven mechanism (i.e., RTK/RAS/RAF-related via RET activation).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>1/5 (20%) in the small triple-negative subset (LC_S1-5) and 1/15 (6.7%) in the double-negative subset (LC_S6-20); replication overall 2/20 (10%).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Authors estimated ~6% overall lung adenocarcinoma based on their sample stratification; in their combined dataset 3/21 (~14.3%). TCGA expression data cited showed RET overexpression in 3/32 (9.4%) samples (not all necessarily fusion-positive).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Observed in tumors that were negative for EGFR, KRAS and EML4-ALK in this study (i.e., the fusion was identified in 'triple-negative' and 'double-negative' samples), suggesting mutual exclusivity with those canonical drivers in these cases; no comprehensive co-occurrence analysis with other drivers (e.g., MET, BRAF, ROS1, NTRK) or with tumor suppressors was reported.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Multiple lines of evidence: (1) Transcript-level evidence with 34 discordant paired-end reads and 60 spanning reads across the fusion junction in RNA-seq; (2) WGS evidence of a 10.6-Mb inversion on chr10 with reads supporting the rearrangement and inversion-specific genomic PCR and Sanger sequencing validating breakpoints; (3) RET exons 12–20 (downstream of breakpoint) are expressed at ~10× the level of RET exons in cancers without rearrangement, indicating fusion-driven overexpression; (4) the fusion preserves KIF5B coiled-coil dimerization domain fused to the RET tyrosine kinase domain — a canonical activating architecture; (5) recurrence in independent primary tumors (replication positives) providing statistical/recurrence support; and (6) prior biological knowledge that RET fusions are oncogenic in other cancers (e.g., papillary thyroid carcinoma).</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No direct in vitro or in vivo functional assays were reported in this paper (no transformation assays, cell-line dependency, Ba/F3, knock-in/knockout, or xenograft drug-response data). The authors infer transforming potential from the preserved RET kinase domain plus KIF5B dimerization domain, high fusion expression, and recurrence, but did not perform experimental functional validation within this study.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Authors propose the KIF5B-RET fusion as a promising molecular target for personalized therapy and suggest development/application of RET-targeted agents; however, no targeted therapy (e.g., RET inhibitors) was tested or reported in this paper and no clinical response data are provided.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>Transcriptome signature specific to the fusion: RET expression is focused on exons 12–20 (post-fusion) with ~10-fold higher expression compared with lung cancers without RET rearrangement. The tumor genome is described as euploid with bimodal allele-frequency distribution; no broad expression or methylation signatures beyond RET overexpression were described for driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>The authors report 10 nonsynonymous somatic mutations (8 SNVs and 2 indels) in the liver metastatic tumor and characterize the genome as euploid with no marked aneuploidy; no formal tumor mutational burden (TMB) per Mb or mutational signature deconvolution (e.g., smoking/APOBEC) was presented specifically for driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Index case (AK55): young age (33 years), never-smoker, poorly differentiated adenocarcinoma with metastases (liver and multiple bones), CK7+ and TTF1+; fusion-positive replication cases identified among primary lung adenocarcinomas that were negative for canonical drivers. Authors note similarity to other fusion-positive lung cancers that occur in younger, never- or light-smokers, but data are limited and no formal statistical association testing was provided.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Limitations discussed: small sample size and low absolute counts of fusion-positive cases; absence of direct functional validation (no cellular transformation or inhibitor-response assays in this paper); possibility of other mechanisms for RET overexpression (amplification, alternative fusions, regulatory mutations) in other datasets; technical detection limits in FFPE-derived primary DNA (primary genome problematic for discovery); WES or targeted panels lacking RNA-seq or WGS might miss structural fusions; variation in exact KIF5B breakpoints between cases; need for larger epidemiologic and functional studies to confirm frequency and driver status.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>A chromosomal inversion fuses the N-terminal KIF5B (bringing a constitutive coiled-coil dimerization domain and its active promoter) to the C-terminal RET tyrosine kinase domain, causing ligand-independent dimerization/auto-phosphorylation of RET kinase and constitutive activation of RTK downstream signaling (oncogenic driver) leading to cellular transformation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer <em>(Rating: 2)</em></li>
                <li>KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer <em>(Rating: 2)</em></li>
                <li>RET and NTRK1 proto-oncogenes in human diseases <em>(Rating: 2)</em></li>
                <li>Use of whole-genome sequencing to diagnose a cryptic fusion oncogene <em>(Rating: 2)</em></li>
                <li>Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>